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ABSTRACT
The piggyBac (PB) transposon has been used in a
number of biological applications. The insertion of
PB transposons into the genome can disrupt genes
or regulatory regions, impacting cellular function, so
for many experiments it is important that PB trans-
position is tightly controlled. Here, we systematically
characterize three methods for the post-translational
control of the PB transposon in four cell lines. We in-
vestigated fusions of the PB transposase with ERT2
and two degradation domains (FKBP-DD, DHFR-DD),
in multiple orientations, and determined (i) the fold-
induction achieved, (ii) the absolute transposition ef-
ficiency of the activated construct and (iii) the ef-
fects of two inducer molecules on cellular transcrip-
tion and function. We found that the FKBP-DD con-
fers the PB transposase with a higher transposi-
tion activity and better dynamic range than can be
achieved with the other systems. In addition, we
found that the FKBP-DD regulates transposon activ-
ity in a reversible and dose-dependent manner. Fi-
nally, we showed that Shld1, the chemical inducer
of FKBP-DD, does not interfere with stem cell differ-
entiation, whereas tamoxifen has significant effects.
We believe the FKBP-based PB transposon induction
will be useful for transposon-mediated genome en-
gineering, insertional mutagenesis and the genome-
wide mapping of transcription factor binding.
INTRODUCTION
Transposons are genetic elements that are able to mobilize
throughout a host genome autonomously. Due to their mo-
bility, DNA transposons and retrotransposons have been
widely used as tools for generating mutation libraries and
for delivering non-viral gene constructs into the genomes
of a variety of organisms (1). The use of DNA transposons
in mammalian genomes, however, was initially impeded by
a lack of active transposable elements. The synthetic resur-
rection of Sleeping Beauty, a Tc1/mariner-like transposable
element of the salmanoid fish genome, initiated the develop-
ment of transposon technologies for use inmammalian cells
(2). Since then, several other transposon systems have been
developed (3–5), including the piggyBac (PB) system, de-
rived from the cabbage loopermothTrichoplusia ni (6). This
system is widely used because the PB transposon consis-
tently exhibits high transposition efficiencies in different cell
lines and organisms (7), can transpose cargos of up to 100
kb without a significant reduction in efficiency (8), mobi-
lizes without leaving footprint mutations at the excision site,
and is amenable to molecular engineering (9). In addition,
the PB system is highly efficient for germ line insertional
mutagenesis in mice and lacks overproduction inhibition
(10). These unique characteristics make the piggyBac trans-
poson an invaluable tool for a wide range of applications,
including stable gene delivery (11), transgene excision (12),
insertional mutagenesis (13) and the mapping of transcrip-
tion factor (TF) binding in eukaryotic genomes (14–16). For
many of these applications, the PB transposon is engineered
to act as a gene trap that will disrupt genes when inserted
into the genome (13), so it is useful to be able to tightly con-
trol PB transposition so that insertion only occurs during
the proper experimental window, and not, for example, dur-
ing the propagation of cell lines or mice. For other applica-
tions, such as the mapping of TF binding to genomic DNA
by PB transposition (14–16), the constitutive activity of the
PBase prevents the determination of the precise timing of
the binding events, a feature that is particularly useful when
studying developmental processes. Therefore, a method for
induction that can tightly regulate the temporal activity of
the PB transposon system is desirable. Furthermore, post-
translational control is appealing because protein activity
can be switched on or off considerably faster than is possi-
ble with transcriptional control schemes (17,18).
Prior to the work presented here, the only exist-
ing inducible PB transposon system that operated post-
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translationally utilized the mutated ligand-binding domain
of the estrogen receptor (ERT2) (9). The PBase-ERT2 fu-
sion is constitutively expressed but is sequestered outside
of the nucleus by the cytoplasmic heat shock protein 90
(HSP90), which binds the ERT2 domain (Figure 1A). In the
presence of a small molecule inducer (4-Hydroxy tamox-
ifen; 4OHT), HSP90 binding is abolished and the PBase-
ERT2 fusion rapidly relocates to the nucleus where it di-
rects transposition. The PBase-ERT2 fusion works well in
several contexts (14), but our early experiences with this sys-
tem revealed that dynamic range of induction varies widely
between different cell types, possibly due to differences in
HSP90 levels, which is not constant across cell types (19–
22). We further found that ERT2-PBase fusions are not
highly active when induced (relative to the unfused trans-
posase, see results). Finally, we found that the chemical in-
ducer 4OHT inhibited the in vitro differentiation of mouse
embryonic stem cells, an observation consistent with simi-
lar reports that 4OHT adversely affects neurogenesis (23),
myelinogenesis (23), myometrial differentiation (24) and
sexual maturation (25).
In light of these observations, we sought to develop a PB
transposon induction system that provides a tightly regu-
lated transposase enzyme that displays a large difference
in activity between the induced and un-induced state, that,
when induced, deposits transposonswith an efficiency equal
to that of the native protein, that is highly active across a
wide variety of cell types, and that is induced with a small
molecule that has minimal effects on general cellular func-
tions. To do so, we characterized and optimized fusions
of the PB transposase with two different destabilized do-
main (DD) proteins, FK506- and rapamycin binding pro-
tein (FKBP) (17) and dihydrofolate reductase (DHFR) (18),
and compared these to the ERT2 based induction system (9)
in four different cell lines. Destabilized domains are small,
inherently unstable proteins that bind small molecules and
have been destabilized by mutation. When fused to PBase,
the mutated domain unfolds and the fusion protein is de-
graded by the proteosome (Figure 1B). However, if the cog-
nate small molecule ligand is provided, the DD is stabi-
lized and the PBase fusion protein is rescued from degra-
dation and transposase activity is restored in a rapid, dose-
dependent and reversible manner. Unlike the ERT2-based
system where induction is mediated by a specific cytoplas-
mic protein HSP90, DD degradation is mediated by the
ubiquitin–proteasome pathway, a common protein degra-
dation mechanism that is active in all mammalian cells
(26,27).
To identify the optimal configuration for each of the three
induction systems, we investigated 15 different fusions of
the PB transposase with FKBP, DHFR or ERT and mea-
sured the fold-induction of activity between the uninduced
and induced states, the maximum transposition rate of the
activated constructs as compared to the unfused piggyBac
transposase, and the effects of two of the inducer molecules
on cellular transcription and differentiation.
MATERIALS AND METHODS
Plasmid construction
The plasmids that contain mutated destabilized domains,
FKBP and DHFR, were purchased from Addgene with ID
31763 and 29326, respectively. The PBase-ERT2 plasmid
(mPBase-L3-ERT2) was a kind gift from Dr Bradley (9).
The coding sequence of mPBase-L3-ERT2 was sub-cloned
into a yeast shuttle vector pRS314 containing CEN6, ARS
and TRP1 to use ‘gap repair’ cloning technique in yeast
cells (Strathern and Higgins 1991). This engineered yeast
shuttle vector was used as a ‘parental’ plasmid (pRM1056)
to derive other variants of PBase constructs by gap repair
method (15). Briefly, PCR-generated sequences were cloned
into linearized vectors by recognizing a 40 bp overlap at
their ends. This 40 bp overlap can be engineered by design-
ing primers for amplification of the desired sequences. For
example, to replace the ERT2 sequence with the FKBP se-
quence, the pRM1056 plasmid was linearized by restriction
digestion that cut the plasmid within the ERT2 sequence.
The FKBP sequence was amplified with a pair of primers
that have a 40 bp sequence that is homologous to pRM1056.
TheFKBPPCRproducts and linearized pBM1056were co-
transformed into yeast cells and the yeast cells were selected
for Trp+ colonies. DNA extracted fromTrp+ yeast colonies
was introduced into E. coli. Finally, the plasmid was iso-
lated by QIAprep Spin Miniprep Kit (QIAGEN) and was
confirmed by Sanger sequencing. The engineered constructs
used in this study are depicted in Figure 2.
Cell culture and neural differentiation
Human embryonic kidneys cell lines (HEK293 and
HEK293T) and human colon adenocarcinoma cell line
HCT116 were maintained in Dubecco’s Modified Eagle
Media (DMEM; Gibco) supplemented with 10% fetal
bovine serum. RW4 mouse embryonic stem cells (ESCs)
were cultured in complete media consisting of DMEM sup-
plemented with 10% new born calf serum, 10% fetal bovine
serum (Gibco) and 0.3 mM of each of the following nucle-
osides: adenosine, guanosine, cytosine, thymidine and uri-
dine (Sigma-Aldrich). To maintain their undifferentiated
state, cells were also cultured in the presence of 1000 U/ml
leukemia inhibitory factor (LIF; Chemicon) and 20 mM -
mercaptoethanol (BME; Invitrogen) in flasks coated with a
0.1% gelatin solution (Sigma-Aldrich).
Mouse ESCs were differentiated into ventral spinal neu-
ral cells using a retinoic acid (RA) and smoothened agonist
induction protocol as described (28). Briefly, ESCswere cul-
tured in suspension on low attachment plates (Corning) in
modified DFK5media consisting of DMEM/F12 base me-
dia (Gibco) containing 5% knockout serum replacement, 1x
insulin transferrin selenium, 50 Mof non-essential amino
acids, 100 mM of BME, 5 mM of thymidine and 15 mM
of the following nucleosides: adenosine, cytosine, guanosine
and uridine.During this process, ESCs aggregate intomulti-
cellular embryoid bodies (EBs). After the first 2 days, the
EBs were moved to a 15 ml of conical and allowed to set-
tle for 5 min. The media was aspirated and replaced with
10 ml of fresh DFK5 containing 2 mM of RA and 600 nM
of smoothened agonist (Millipore). EBs were then cultured
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Figure 1. Schematic illustration of the ERT2 and destabilized domain (DD) based PiggyBac (PB) transposon induction systems. (A) For the ERT2-based
PB transposon induction system, the PBase-ERT2 fusion is constitutively expressed but sequestered outside of the nucleus by HSP90, which binds the
ERT2 domain. In the presence of ER antagonist 4-OHT, HSP90 dissociates and the PBase-ERT2 fusion rapidly relocates to the nucleus where it directs
transposition. (B) For the DD-based PB transposon induction system, a DD (either FKBP or DHFR) was fused to the PBase. The DD confers the
instability to the fused protein such that the PBase fusion protein was constitutively degraded. However, binding of a small molecule ligand (Shld1 for
FKBP; TMP for DHFR) to the DD prevents PBase from degradation and stabilizes it.
Figure 2. Schematic illustration of the constructs used in this study. For the helper constructs: PBase, PiggyBac transposase; CMV, cytomegalovirus
promoter; pA, bovine growth hormone polyA signal. FKBP, a destabilizing domain derived from FK506 and rapamycin binding protein. DHFR, a
destabilizing domain derived from Escherichia coli dihydrofolate reductase; YFP, yellow fluorescent protein; ERT2, mutated ligand-binding domain of the
estrogen receptor; Cumate, cumate operator (mutated cmv promoter). For the donor construct: 5′TR-puro-3′TR contains the minimal PB terminal repeats
(5′LR and 3′TR) flanking a PGK promoter driven puromycin resistance cassette; EF1, elongation factor 1 promoter; GFP, green fluorescent protein.
on the adhesive plates (Corning) for an additional 4 days
for further differentiation, and media was replaced every 2
days.
Cell transduction and transgenic cell line generation
All lentiviruses used for cell transduction were produced by
the Hope Center Viral Vectors Core at Washington Univer-
sity School of Medicine. A CymR-expressing HEK293 cell
line was made by transducing the cell with lentivirus con-
taining the cumate operator repressor driven by an EF1a
promoter at a multiplicity of infectivity of 20 to ensure
that CymR is overexpressed. Two days after transduction,
neomycin was added to the culture medium (500 ng/ml)
and maintained for 7 days. Then, the CymR-expressing
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HEK293 cell line was further transduced with lentivirus
containing an FKBP-PBase-FKBP-IRES-RFP fusion gene
driven by a cumate inducible promoter at multiplicity of in-
fectivity of 0.5 to favor single-copy integration. To obtain a
pure population, transduced cells were then sorted for red
fluorescent protein (RFP) positive cells.
Cell transfection and drug administration
All plasmids used for the transfection of cells were prepared
using EndoFree Plasmid Maxi Kit (Qiagen) following the
manufacturer’s protocol. About 105 cells were electropo-
rated with a total of 0.6 g of DNA (0.1 g helper plasmid
and 0.5 g donor plasmid) by the Neon transfection system
(Invitrogen) and plated to one well of a 6-well plate. Im-
mediately upon transfection, cells were treated with 1 M
4-hydroxy tamoxifen (4OHT, Sigma) for the ERT2 based
induction system, 1 M Shld1 (Clontech) for FKBP based
induction system, 10 M trimethoprim (TMP, Sigma) for
the DHFR based induction system. Negative controls were
mock-treated with 95% ethanol as vehicle. For the trans-
genic cell line expressing inducible PBase driven by a cu-
mate promoter, only donor plasmid was used in transfec-
tion. Cumate inducer (System Biosciences) was added at
concentrations ranging from 0 g/ml to 70 g/ml to reg-
ulate the strength of cumate promoter. For the purpose
of reproducibility, experiments were done in triplicates. To
select cells in which the PB transposon transposed, cells
were trypsinized 2 days after transfection and cultured on
10 cm dish (Corning) with 10 ml fresh media containing
puromycin (1 g/ml). The puromycin selection normally
takes 7 days before visible cell colonies are formed.
For experiments testing the reversibility of the FKBP-
based PB transposon system, Shld1 (1 M) was added to
the culturemedium immediately after transfection. One day
after transfection, a small aliquot of cells were used for
imaging and flow cytometry analyses and the rest of the
cells were passaged to a 12-well plate and provided fresh
Shld1-free medium. The passaged cells were grown to about
100% confluence before another passage to a 12-well plate.
One well of cells were used for imaging and flow cytometry
analyses every day. After 3 days of destabilization, the cells
were treated with fresh medium containing 1 M Shld1 to
re-stabilize the FKBP-YFP-PBase fusion protein. The re-
stabilization lasted for another 3 days during which the cells
were analyzed by flow cytometry every day.
Cell colony staining and counting
The visible drug-resistant cell colonies were fixedwith phos-
phate buffered saline (PBS) containing 4% paraformalde-
hyde for 1 h and then stainedwith 1%methylene blue in 70%
EtOH for 30 min, washed in distilled water and air-dried
overnight. Colonies with diameters more than 0.3 mm were
counted by ImageJ software (National Institutes ofHealth).
The number of puromycin-resistant colonies formed from
the cells transfected with both donor and helper plasmids
was normalized to that with donor and helper backbone
plasmids (yeast shuttle vector pRS314) prior to any fur-
ther calculations. The transposition activity of a PBase fu-
sion protein was calculated as the normalized number of
colonies from the inducible domain (i.e. FKBP, DHFR or
ERT2) fused PBase divided by that from ‘wild type’ unfused
PBase. For experiments that used the transgenic cell line
expressing FKBP-PBase-FKBP driven by a cumate pro-
moter, we used normalized number of puromycin-resistant
colonies to estimate the transposition activity due to the un-
availability of the cell line expressing ‘wild-type’ unfused
PBase. Fold-induction was calculated as the normalized
number of colonies from the induced samples divided by
that from untreated samples.
Imaging and flow cytometry
Fluorescent images were taken on Zeiss Axioskop fluores-
cence microscope equipped with a QICAM FAST 1394
digital CCD camera. Cells were grown to 90% confluence,
trypsinized from the plate and suspended in PBS, washed
once with PBS and resuspended in Hank’s balanced salt so-
lution supplemented with 2mMethylenediaminetetraacetic
acid. Cellular fluorescence was analyzed on an iCyt Reflec-
tion HAPS2 cell sorter at the Washington University Site-
man Flow Cytometry Core. The gate was set relative to the
cells transfected with non-fluorescent control plasmids to
eliminate background. Cells transfected with a positive con-
trol fluorescent reporter plasmid were also used to elimi-
nate false positive singles. About 10 000 cells were analyzed
from each FACS and post-sort analysis was performed with
FloJo software to obtain the percentage of fluorescent pos-
itive cells.
RNA extraction and sequencing
Total RNA was isolated from the RW4 mouse ESCs us-
ing the PureLink RNA Mini kit (Ambion) according to
the manufacturer’s instructions. The quantity of RNA was
measured using a spectrophotometer (NanoDrop 2000c;
Thermo Scientific). Samples with a RNA concentration
(A260/A280 ≥1.8 ng/l) and purity (A230/A260 ≥ 2.0
ng/l) were selected. The Agilent 2100 Bioanalyser was
used to determine the RNA integrity number. The degra-
dation level was identified using the RNA 6000 Nano
LabChip kit (Agilent). Samples withRNA integrity number
> 9.8 were further processed using TruSeq mRNA Library
Preparation Kit (Illumina) and then sequenced by Illumina
MiSeq platform at the Genome Technology Access Center
at Washington University in St. Louis. The gene expression
data generated for this study can be found under the NCBI
Gene Expression Omnibus accession number GSE78857.
The expression data is also publicly available at the Center
for Genome Sciences by request.
Reads mapping and statistical analysis
Trimmomatic (v0.32) (29) was employed on RNA-Seq
FASTQ files to clip the illumina adaptors and remove the
reads of low quality. The cleaned reads were mapped back
to mm10 genome reference from UCSC database using
STAR (v2) (30). We used the HTSeq package (31) to esti-
mate the count of uniquelymapped reads for each of the an-
notated genes in the mm10 gene transfer format (.GTF) file.
Differential expressed genes were analyzed withR (v 2.13.0)
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using DESeq (v1.4.1) (32) available in Bioconductor (v 2.8).
The resulting P-values were adjusted using the Benjamini–
Hochberg correction and only genes that were significant at
a false discovery rate of 0.05 were considered as expressed.
For other comparisons between different experimental con-
ditions, the statistical significance was assessed by paired




We evaluated and optimized three induction systems for
their abilities to provide tight post-translation control over
the PB transposon. We used one degradation domain (DD)
derived from human FKBP12 (FKBP) (17) and another
from E. coli DHFR (18) and compared these against the
ERT2-based system in four different cell lines: human em-
bryonic kidney cells (HEK293 and HEK293T), human col-
orectal cancer cells (HCT116) and RW4 mouse ESCs. To
obtain the most efficient induction possible, a number of
different fusions constructs were investigated for each sys-
tem (Figure 2). We fused DD or ERT2 induction domains
in-frame at the N terminus, C terminus or at both termini
of the PBase. For N terminal fusion proteins, an 18 amino
acid linker sequence was included between the PBase and
the induction domain (33). For the C terminal fusion pro-
tein, a 24 amino acid linker was added between the PBase
and induction domain (9).
In order to evaluate these different fusion proteins, we
needed a simple, robust way to measure PB transposition.
We adopted the commonly used method of co-transfecting
cells with two plasmids: a ‘helper’ plasmid expressing the
PBase and a ‘donor’ plasmid carrying the PB transposon
with a drug-resistance marker (15). Once transfected into
the host cells, the PBase mobilizes the transposon from the
donor plasmid and integrates it into the host genome, con-
ferring the cell with drug resistance. The number of drug-
resistant colonies is closely correlated with the number of
transposon integration events and is a key indicator of the
efficiency of the PB transposon system (9,15,34). We used
this system to measure, for each post-translational control
system, the absolute transposition efficiency of the activated
construct relative to the unfused piggyBac transposase, and
the fold-induction achieved by eachmethod in four different
cell lines. We then went on to optimize the most promising
system, characterize the dynamics of the temporal control
achieved by the optimal system and evaluate the effects of
two of the inducer molecules on cellular transcription and
function.
Evaluating the transposition efficiencies of inducible PBase
We first measured the transposition activity of the induced
PBase fusion proteins relative to that of unfused PBase.
The transposition activity for each variant of helper con-
structs was obtained by transfecting the above-mentioned
four cell lines with an equimolar ratio of donor and helper
plasmids in the presence of chemical inducers (Shld1 for
FKBP fusions; TMP for DHFR fusions; 4OHT for ERT2
fusions). Typical images of stained colonies from negative
control, inducer-treated and non-treated co-transfected ex-
periments, and positive control with unfused PBase are
shown in Figure 3A. The induced transposition activities
relative to unfused PBase are shown in Figure 3B, and raw
colony counts are provide in Supplementary Figures S1 and
S2. In our assays, the DD-based induction systems had
significantly higher activities than the ERT2-based induc-
tion system in all cell lines. The highest PBase activity was
observed for the constructs of FKBP-PBase and DHFR-
PBase, both of which had activities that were ∼95% of
‘wild-type’ levels. In contrast, all of the ERT2 fusion pro-
teins displayed activities less than 25% that of the unfused
PBase. Thus, we conclude that, under inducing conditions,
the FKBP andDHFRDDshave little effect on PBase trans-
position activity while ERT2 appears to significantly inter-
fere with the PBase activity. For the two DD-based induc-
tion systems, the transposition activities between N and C
terminally tagged PBase fusions are not significantly differ-
ent (P> 0.05). However, we observed a significant decrease
of PBase activity when both termini were attached to either
DD, suggesting that at least one terminus should be exposed
for near-optimal PBase transposition activity.
The FKBP DD system achieved the highest fold-change be-
tween induced and uninduced states
We next sought to quantify how tightly the different induc-
tion systems regulated the PBase protein. To do so, we again
transfected the four cell lines with donor and helper plas-
mids; however, in this assay, we omitted the small-molecule
inducers.We found that theDHFR-based PB induction sys-
tem had amuch higher background than did the FKBP and
ERT2-based ones (Figure 3C). To determine which PBase
fusion protein provided the largest dynamic range, we used
the corresponding induced and non-induced transposition
rates to calculate the fold-induction for each protein (Figure
3D). This analysis revealed that the FKBP-based induction
system displayed a significantly higher fold-induction than
both the DHFR and ERT2-based systems in all cell lines
(P< 0.05). The FKBP-PBase-FKBP fusion protein showed
the highest fold-induction while the ERT2-PBase-ERT2 fu-
sion protein showed the lowest. Taking fold-induction and
the absolute activity of induced PBase into consideration,
the FKBP-based inducible PB transposon system outper-
formed its DHFR and ERT2-based counterparts.
HSP90 levels correlate with the dynamic range of the ERT2
system
The dynamic ranges of the ERT2 controlled PBase fu-
sion proteins were highly variable across the different cell
lines (Figure 3D). For example, the PBase-ERT2 fusion dis-
played a 17-fold change in transposase activity between in-
duced and uninduced conditions in mouse RW4 embry-
onic stem cell, but a significantly lower fold-induction in
the other cell lines (P < 0.05). One possible explanation
for this observation is that the HSP90 protein is typically
highly expressed in mouse ES cells. HSP90 is the molecule
that sequesters the fusion protein in the absence of inducer,
and it has been previously reported the HSP90 RNA (35)
and protein (36) levels are significantly higher in mouse ES
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Figure 3. The performance of different helper constructs in DD and ERT2 based PB transposon induction systems. (A) Typical images of colony forming
and staining assays to evaluate the transposition efficiency. The scale bar in the enlarged image equals 0.1 mM. The construct used is FKBP-PBase. (a)
Cells transfected with donor and helper backbone plasmids (yeast shuttle vector pRS314) were used to estimate the background or random insertions. (b
and c) Cells transfected with FKBP-PBase and donor plasmids either in the absence or presence of Shld1 were used to evaluate the transposition efficiency.
(d) Cells transfected with unfused PBase and donor plasmid were used to estimate the maximum transposition efficiency. (B) Induced PBase activity of
different PBase fusions relative to wild-type PBase across four cell lines. The number of puromycin-resistant colonies formed from the cells transfected
with both donor and helper plasmids was normalized to that with donor and helper backbone plasmids prior to any further calculations (background
subtraction). The induced transposition activity of an inducible domain (i.e. FKBP,DHFRor ERT2) fused PBase was calculated as the normalized number
of colonies from the PBase fusion divided by that from ‘wild type’ unfused PBase. Experiments were done in triplicate. (C) Non-induced PBase activity of
different PBase fusions across four cell lines. Experimental conditions were the same as in B except that no drug was added for the non-induced samples.
(D) Fold induction of different PBase fusions across four cell lines. The induction fold was calculated as the normalized number of colonies from induced
samples in B divided by that from untreated samples in C.
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cells than in differentiated cell lines or embryoid bodies. To
confirm HSP90 is indeed highly expressed in our mESCs,
we performed RNA sequencing on the RW4 and HCT116
lines. We found that the beta-actin normalized HSP90 ex-
pression level in the RW4 mouse ES cell line was about
4-fold higher than that in HCT116 cell line (Supplemen-
tary Data 1 and 2), which is consistent with the theory that
HSP90 levels explain the differences observed betweenRW4
mouse ESCs and HCT116 cells.
There is a trade-off betweenmaximal PBase activity and fold-
induction
In the FKBP-based induction system, the PBase fusion
protein shuttles between the cytoplasm where FKBP-
directed degradation occurs and nucleus where PB transpo-
sition occurs. Therefore, we hypothesized that this nucleo-
cytoplasmic transport could be fine-tuned to create an in-
duction system with both efficient transposition and rapid
degradation. To try to further improve transposition effi-
ciency, we fused the nuclear localization sequence (NLS)
from the SV40 large T-antigen upstream of, and in-frame
with, the FKBP-PBase fusion, which had the highest trans-
position activity in our previous tests (Figure 3B). We rea-
soned that the NLS should direct more fusion protein to
the nucleus, increasing the transposition rate upon admin-
istration of Shld1. We used transient transfection to in-
troduce an equimolar ratio of NLS-FKBP-PBase fusion-
carrying plasmid and donor plasmid across four different
cell lines, and compared the results to that of FKBP-PBase
plasmid without the NLS. After induction, the engineered
fusion protein (NLS-FKBP-PBase) displayed an increase
in transposition activity relative to the FKBP-PBase fusion
protein (Figure 4A, P < 0.05). However, we also observed
higher background transposition in the uninduced sample
for this construct. As a result, the fold-induction for the
NLS-FKBP-PBase fusion was lower than that of FKBP-
PBase (Figure 4B, P< 0.05). This suggests that the NLS se-
quence sequesters some protein in the nucleus and prevents
efficient degradation in the absence of Shld1. Based on this
observation, we concluded that adding NLS to PBase fu-
sion protein is not optimal for an inducible PB transposon
system.
To test the possibility of further reducing the background
transposition that occurs in the absence of chemical inducer,
wemade twomore fusion constructs. One contains two tan-
dem FKBP domains at the N terminus of PBase (Figure 2,
construct 5) since our previous results showed that an N-
terminally tagged PBase was more tightly regulated than
the corresponding C-terminally tagged PBase. The second
construct utilized three FKBP domains: two in tandem on
the N-terminus and one on the C-terminus (Figure 2, con-
struct 6).We tested the transposition efficiency and dynamic
range of these constructs as before, and found that the
triple FKBPs fusion protein (FKBP-FKBP-PBase-FKBP)
showed the highest fold-induction in all cell lines (Figure
4A, right panel), followed by the double FKBPs fusion pro-
teins (FKBP-PBase-FKBP and FKBP-FKBP-PBase). All
three constructs achieved a significantly higher fold induc-
tion than did FKBP-PBase (P < 0.05).
We next examined the maximal induced transposition ef-
ficiency of these constructs relative to the unfused PBase
(Figure 4B, right panel). We found that the transposition
efficiencies of FKBP-FKBP-PBase-FKBP, FKBP-FKBP-
PBase and FKBP-PBase-FKBP were 60%, 79% and 80%
of the unfused PBase, which is significantly lower than the
95% relative activity we observed for FKBP-PBase (P <
0.05), indicating that transposition activity gradually de-
creased when more FKBP domains were added to PBase.
Taken together, these results suggest that there is a trade-off
between the efficient degradation of the PBase fusions un-
der non-inducing conditions and the enzymatic activity of
these fusions under fully inducing conditions (Figure 4C).
Specifically, if high activity upon induction is the objective,
then the FKBP-PBase fusion is optimal, while if a high fold-
change in induction is required, the FKBP-FKBP-PBase-
FKBP fusion is the best choice.
Fusion protein levels can be tuned to achieve low background
transposition and high inducibility
For some applications, it is not important to obtain the
maximum possible PBase activity, but it is instead prefer-
able to have an assay with low background levels and to
achieve a large fold-change in activity upon induction. We
reasoned that the high background levels observed in Fig-
ures 3 and 4 might be due to the fact that the PBase-DD
fusion proteins were all highly expressed and therefore the
proteasome was getting overloaded. To test this hypothesis,
we created lentivirus containing an FKBP-PBase-FKBP-
IRES-RFP fusion gene under the control of a cumate in-
ducible promoter (37) (Figure 2, construct 9), which allows
gene expression to be tuned by varying the cumate concen-
tration in the culture media. Next, we infected cymR ex-
pressing HEK 293 cells, and isolated transduced cells by
performing FACS to purify RFP positive cells. We trans-
fected these cells with donor plasmid (Figure 2, construct
16), titrated FKBP-PBase-FKBP protein levels by culturing
the cell with varying amounts of cumate, in the presence or
absence of Shld1, and determined PBase activity by count-
ing puromycin resistant colonies as previously described.
The results are shown in Figure 5. As lower concentra-
tions of cumate were added to the media, much lower back-
ground and larger fold-changes in induction were achieved.
For example, when 10 g/ml cumate was added to the me-
dia, no background transposition was observed, and we ob-
served a more than 100-fold change in PBase activity after
induction with Shld1. These results demonstrate that, when
the FKBP-PBase-FKBP protein is expressed at moderate
levels, this system has essentially no background transposi-
tion yet is still robustly inducible. This level of control comes
at some cost, however, as the maximum level of PBase ac-
tivity is roughly one-fourth the maximum rate we observed
(i.e. compare the 10g/ml cumate and Shld1 culture condi-
tion to the PBase activity of cells grown with 70 g/ml cu-
mate and Shld1). For experiments that do not require rapid,
post-transcriptional induction, it is possible to have the best
of both worlds, namely zero background and high absolute
activity, by growing cells in the absence of cumate and Shld1
and then adding both chemicals to induce transposition.
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Figure 4. Optimization of the induced transposition activity and fold induction for FKBP-based PB transposon induction system. (A) Induced trans-
position activity of different PBase fusion proteins relative to wild-type PBase across four cell lines. Experiments were done in triplicates. The induced
transposition activity of a PBase fusion protein was calculated as the normalized number of colonies from the PBase fusion in the presence of corre-
sponding chemical inducer divided by that from ‘wild type’ unfused PBase. (B) Fold induction of different PBase fusion proteins across four cell lines. The
induction fold was calculated as the normalized number of colonies from chemical inducer treated samples divided by that from untreated samples. (C)
Comparison of the induced transposition activity with the fold induction for different PBase fusion proteins across four cell lines.
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Figure 5. The performance of the cumate-regulated FKBP-based PB transposon induction system. Cumate was included in culturemedia at concentrations
ranging from 70 g/ml (full induction of the cumate promotor) to 0 g/ml (no induction). For each cumate concentration, Shld1 (yellow) or vehicle (70%
ethanol, blue) was added to the medium to activate the PB transposon induction system. The normalized number of puromycin-resistant colonies and the
fold-activation are plotted at different cumate/Shld-1 concentrations.
The FKBP-PBase-FKBP protein levels can be tuned post-
transcriptionally
We next sought to determine if PB activity could be post-
transcriptionally tuned by adjusting Shld1 concentration.
To do so, we transfected four cell lines with donor and
helper plasmids (Figure 2, construct 3 and 16) and subjected
these transfected cells to various concentrations of Shld1: 0
nM, 8 nM, 40 nM, 200 nM and 1 M. We calculated the
normalized number of puromycin resistant cell colonies for
each Shld1 concentration.We found that the colony number
increased almost linearly with the increase of the concentra-
tion across all cell lines (r= 0.81, Figure 6A), indicating the
FKBP-based PB transposon induction is tunable and dose-
dependent.
Counting puromycin-resistant colonies reveals the num-
ber of cells with at least one integrated transposon; however,
it does not provide information about the average number
of transposition events that have occurred per cell. To ad-
dress this, we also measured PBase activity at various con-
centrations of Shld1 using an alternative readout for trans-
position.We created a donor vector (Figure 2, construct 17)
in which a GFP gene is split by a PB transposon, render-
ing it inactive (Supplementary Figure S3A). Nuclear PBase
will excise the transposon creating a functional GFP gene
that is then expressed, and so the average fluorescence of
the cell population is proportional to the number of trans-
poson excision events. The results of these experiments are
shown in Supplementary Figure S3B and S3C. The mean
cellular fluorescence increases monotonically with Shld1 in
a near-linear fashion, validating the results obtained with
the puromycin donor, and supporting the thesis that PB in-
duction is tunable and dose-dependent.
The FKBP based PBase system is reversible
To determine if the degradation of FKBP-PBase is re-
versible, we fused a yellow fluorescent protein (YFP) in-
frame between FKBP and PBase by an 18 amino acid linker
at N terminus of PBase (33) (Figure 2, construct 7), al-
lowing the visualization and semi-quantitative analysis of
the expression of the PBase fusion by monitoring fluores-
cence intensity. The four cell lines mentioned above were
transfected with the helper plasmid (FKBP-YFP-PBase)
and separately, a control plasmid (YFP-PBase). Shld1 was
added to the culture medium immediately upon transfec-
tion and incubated for one day. Next, the cells were pas-
saged and cultured in drug-free medium for three days. Fi-
nally, Shld1 was added back again to re-stabilize the FKBP-
YFP-PBase fusion for another three days. The typical im-
ages from fluorescence microscopy at three turning points
were shown in Figure 6B: (i) one day after treatment with
Shld1, (ii) three days after removing Shld1 and (iii) three
days after retreatment with Shld1. We also measured the
percentage of YFP positive cells every day by flow cytome-
try. To control for plasmid dilution during the experiment,
the percentages of YFP positive cells from the FKBP-YFP-
PBase fusions were normalized by the percentage of YFP
positive cells in the corresponding control YFP-PBase sam-
ples. The results are plotted in Figure 6C. Taking Figure 6B
and C together, we observed a sharp drop in the YFP posi-
tive cell population at the second measurement time point,
indicating that without the inducer Shld1, the fusion pro-
teins were quickly degraded. The normalized percentage of
YFP positive cells was nearly completely restored to the
original value three days after Shld1 was reapplied, indicat-
ing the system is reversible. By fitting the curves in Figure
6C to an exponential decay functions, we estimated the half-
life of the FKBP-PB fusion protein to be 30 h. Our results
suggested FKBP-based inducible PB transposon system is
tunable and reversible.
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Figure 6. Tunability and reversibility of the FKBP-based PB transposon induction system. (A) FKBP-PBase-FKBP activity is tunable. Cells were trans-
fected with donor and helper plasmids (FKBP-PBase-FKBP) and subjected to various concentrations of Shld1: 0 nM, 8 nM, 40 nM, 200 nM and 1
M. The normalized number of puromycin-resistant colonies observed is plotted versus the Shld1 concentration for four cell lines. (B) Shld-1 induction
is reversible. Fluorescent images are taken at various timepoints after induction with 1uM Shld1 or removal of Shld1 from transfected HEK293T cells.
The white scale bar equals 50 m. The red arrows indicate the time points of measurement. Bright field and fluorescent images were shown at top and
bottom panel respectively. (C) Quantification of the reversibility of Shld-1 induction. The cells imaged in panel B were quantified by FACS. The normalized
percentage of YFP positive cells is plotted at each time point for four cell lines.
Unlike 4OHT, Shld1 does not interfere with general cellular
functions
It has previously been reported that 4OHT adversely af-
fects developmental processes such as neurogenesis (23),
myelinogenesis (23), myometrial differentiation (24) and
sexual maturity (25). Therefore, we next sought to test if
cells treated with Shld1 or 4OHT display any developmen-
tal phenotypes. We added these chemicals to EBs gener-
ated from mouse ESCs, and differentiated them into ven-
tral spinal neural cells with retinoic acid and smoothened
agonist (28). We found that in the presence of 2 M 4OHT,
EB differentiation was inhibited and neuron-like cells were
not generated. In contrast, EBs that were mock-treated or
treated with 2 M Shld1 differentiated normally (Figure
7A). These results suggest that 4OHT inhibits EB differen-
tiation, while Shld1 does not.
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Figure 7. The effects of chemical inducer on RW4 mouse ES cells (ESCs). (A) Images of embryoid bodies (EBs) and differentiated EBs treated with (a)
95% ethanol as vehicle, (b) 2 M Shld1 and (c) 2 M 4-hydroxytamoxifen during EB formation and neural differentiation from mouse ESCs to neural
lineages. (B andC) The comparison of gene expression profile of drug-treated samples with that of mock-treated ones. Experiments were done in duplicate.
Mean of the normalized counts from drug-treated samples was plotted against log2 fold change of drug-treated samples to mock-treated ones under the
category of (B) Shld1 versus Mock and (C) 4OHT versus Mock. Red dots indicate the differentially expressed genes.
To further explore the effects of the inducer molecules on
differentiation, we sought to quantify the extent to which
these Shld1 and 4OHT perturb the transcriptional network
of EBs. EBs were treated with Shld1 and 4OHT, respec-
tively, for 2 days, inducedwith retinoic acid and smoothened
agonist for 2 more days, and then subjected to gene expres-
sion profiling by RNA-Seq. Cells mock-treated with 95%
ethanol as vehicle were used as controls. For each condition,
two biological replicates were performed and correlation
co-efficiencies between them are above 0.96 (Supplemen-
tary Figure S5), demonstrating reproducibility. The mean
of the normalized counts from drug-treated samples was
plotted against log2 fold change of drug-treated samples
to mock-treated ones under the category of Shld1 versus
Mock and 4OHT versus Mock (Figure 7B and C). A sig-
nificant change of gene expression profile was observed for
4OHT-treated samples but not in Shld1-treated ones. Af-
ter Benjamini–Hochberg correction for multiple hypothe-
ses (see methods), we identified 260 differentially expressed
genes in the 4OHT-treated samples (Supplementary data 3).
We performed gene ontology analysis on these genes using
the DAVID Bioinformatics package (38,39) and functional
annotation clustering revealed that ‘heat shock’ and ‘stress
response’ were the most over-represented terms (adjusted
P < 0.01), a result that supports our experimental obser-
vation that 4OHT is toxic to EBs. In contrast, only one
gene (FOS, NM 005252) was differentially expressed in the
Shld1 treated samples, suggesting that this chemical has lit-
tle to no effect on the transcriptional network that controls
development of EBs.
DISCUSSION
We have systematically characterized, in four cell lines, 15
different PB transposase fusion proteins representing three
different induction systems.We found that the FKBP-based
system achieved the broadest dynamic range of induction
across four cell lines. Remarkably, in the presence of chem-
ical inducer, this system had transposition efficiencies that
were almost as high (∼95%) as the ‘wild-type’ PB transpo-
son. Our results, coupled with the fact that Shld1 does not
affect ESC development, suggest that this will be the pre-
ferred induction system for many types of experiments, es-
pecially those involving cellular differentiation or organis-
mal development.
In our plasmid-based experiments (Figure 3), we ob-
served a lower dynamic range for the ERT2-based PB trans-
poson induction system that was previously observed by
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Cadinanos et al. (∼20-fold versus ∼270-fold) (9). This dis-
crepancy is likely explained by the fact that, in our donor
plasmid, the puromycin resistance gene is driven by a PGK
promoter whereas in Cadinanos et al., the puromycin re-
sistance gene is promoterless and downstream of a splic-
ing acceptor site. In that system, only insertions in active
genes will produced colonies, but in our system, all inser-
tions will produce resistant clones. This would explain why
we observed more background puromycin-resistant clones
when the transposase was not induced since both studies
normalized to background and small absolute changes in
the denominator can lead to large changes in the calculated
fold change.
The moderate background transposition of the DD in-
duction system observed in our plasmid experiments (Fig-
ure 3) was largely the result of the over-expressed fusion pro-
tein overloading the cells’ proteasome system, since when
the FKBP-fused PBase was placed under the control of
a cumate-titratable promoter and delivered at lower copy
number, we observed no background transposition while
still achieving robust transposition after induction. Since no
background hops were observed at several cumate concen-
trations, the fold-induction of the system is not defined; we
conservatively estimate it as >100-fold.
An interesting difference betweenDD-based systems and
the ERT2 based system is that the performance of the
DD systems was more uniform across the difference cell
lines. We hypothesize that this difference is due to the fact
that the DD system uses the ubiquitin–proteasome system
to constantly degrade FKBP-fused PBase. The ubiquitin–
proteasome system is a general degradation machinery and
uniformly expressed and works efficiently in all mammalian
cell types. In contrast, the ERT2-based induction system is
dependent on a specific cytoplasmic protein HSP90, a gene
whose expression varies widely between cells. Our RNA se-
quencing data showed that the HSP90 expression level in
theRW4mouse ES cell line is about 4-fold higher than in the
HCT116 cell line, suggesting that a low amount of HSP90
levels may lead to either a high basal activity without induc-
tion or a low induced activation.
In the FKBP-based PB transposon induction system, we
observed that N-terminally tagged PBase (FKBP-PBase)
has a higher fold induction than the C-terminally tagged
counterpart (PBase-FKBP), which may suggest that FKBP
fused at the N terminus is more likely to be exposed and
thereby recognized by the proteasome than when fused to
theC terminus. This terminal specific higher activitymay re-
late to the distribution of functional components of PBase.
It was reported that the PBase has a functional nuclear tar-
geting signal in the 94 C-terminal residues (40). C-terminal
fused PBase, therefore, is more likely to negatively affect the
nuclear translocation of the PBase protein, which in turn
increases the likelihood of being recognized and degraded
by the proteasome in the cytoplasm. We also observed that
fusing additional DDs to the PB transposase increases the
fold-change in activation between the induced and unin-
duced conditions. However, the addition of multiple DDs
causes the absolute activity of the induced protein to be
significantly reduced, suggesting a trade off between how
tightly a protein can be regulated, and its maximum activity
in the induced state. Our results suggest that the FKBP-DD
is optimal when a high level of PB transposition is preferred,
while FKBP-FKBP-PBase-FKBP is the choice when tight
regulation is the priority.
The FKBP system will be likely prove considerably more
useful than then ERT2 system for the study developmental
processes, since we found that the ERT2 inducer tamoxifen
is a strong inhibitor of embryoid body differentiation. Our
results are consistent with previous reports that tamoxifen
has deleterious effects on a number of developmental sys-
tems (23–25). In contrast, we found that Shld1, the FKBP
inducer, has no such phenotype, and furthermore, few tran-
scriptional changes were observed in our RNA-Seq analysis
of embryoid bodies treated with Shld1. Together, these re-
sults suggest that the FKBPDD system is prefereable to the
ERT2 system for experiments involving cellular differentia-
tion.
In summary, we have investigated the applicability of
three different induction systems to the PB transposase by
characterizing and optimizing 15 fusion constructs to de-
velop a broadly applicable PB transposon induction sys-
tem based on the FKBP degradation domain. This induc-
tion system satisfies five important criteria: (i) The sys-
tem has a low basal transposition activity when ‘off ’ and
maintains high transposition activity when ‘on’; (ii) The
PBase fusion protein shows high transposition activity al-
most equal to that of the unfused ‘wild type’ PBase; (iii)
The system can be applied across different cell lines with
high performances; (iv) The induction is reversible and
responds in a dose-dependent manner; (v) The chemical
inducer does not interfere with general cellular function.
Taken together, our experiments suggest that this system
can be readily applied to diverse research applications such
as PB transposon-mediated genome engineering and tech-
nology development.
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Supplementary Data are available at NAR Online.
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